GlaxoSmithKline’s new generation H5N1 split antigen pre-pandemic flu vaccine has been accepted for review by the Committee for Medicinal Products for Human Use (CHMP) in Europe. This vaccine utilizes GSK’s proprietary adjuvant system technology, which allows a very low amount of antigen to be used to elicit a strong seroprotective response, known as the ‘antigen-sparing’ effect. A recent trial conducted in Belgium involving the H5N1 vaccine has shown that two very lo...